All In Biotech

Drug Trial Radar · NCT00406341

Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation

Phase 3 Confimatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treament of Postoperative Inflammation

Last checked: Nov 20, 2026Latest source record: Dec 4, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Apr 2004

Primary completion

Not stated

Study completion Mar 2005

Sponsor

Lead sponsor
Sirion Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Dec 4, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase 3 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of postoperative inflammation.

Conditions

  • Inflammation

Interventions

  • Difluprednate Ophthalmic EmulsionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The changes in anterior chamber cell score at day 14 after start of instillation from the baseline level (differences from the baseline score) were compared between the 2 treatment groups.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.